Connection

Co-Authors

This is a "connection" page, showing publications co-authored by KEYUR PRAVINCHANDRA PATEL and L JEFFREY MEDEIROS.
Connection Strength

7.605
  1. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48?Hours of Sample Collection. J Mol Diagn. 2019 01; 21(1):89-98.
    View in: PubMed
    Score: 0.661
  2. TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. Mod Pathol. 2013 Feb; 26(2):195-203.
    View in: PubMed
    Score: 0.426
  3. Predictive and prognostic molecular biomarkers in lymphomas. Pathology. 2024 Mar; 56(2):239-258.
    View in: PubMed
    Score: 0.233
  4. Corrigendum to "Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship." [Modern Pathology 34 (2021) 2154-2167]. Mod Pathol. 2023 Dec; 36(12):100355.
    View in: PubMed
    Score: 0.231
  5. Classic Hodgkin lymphoma with marked granulomatous reaction: A clinicopathologic study of 20 cases. Hum Pathol. 2023 04; 134:114-123.
    View in: PubMed
    Score: 0.218
  6. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res. 2022 05; 116:106827.
    View in: PubMed
    Score: 0.206
  7. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102.
    View in: PubMed
    Score: 0.204
  8. Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Mod Pathol. 2021 12; 34(12):2154-2167.
    View in: PubMed
    Score: 0.197
  9. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.
    View in: PubMed
    Score: 0.184
  10. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet. 2019 04; 233-234:21-31.
    View in: PubMed
    Score: 0.167
  11. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.
    View in: PubMed
    Score: 0.164
  12. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS One. 2018; 13(9):e0204218.
    View in: PubMed
    Score: 0.162
  13. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018 07 01; 124(13):2704-2713.
    View in: PubMed
    Score: 0.157
  14. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S62-S74.
    View in: PubMed
    Score: 0.149
  15. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):395-403.e1.
    View in: PubMed
    Score: 0.137
  16. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.
    View in: PubMed
    Score: 0.137
  17. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol. 2015 Nov; 144(5):746-55.
    View in: PubMed
    Score: 0.133
  18. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3.
    View in: PubMed
    Score: 0.129
  19. Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization. Leuk Lymphoma. 2014 Nov; 55(11):2538-48.
    View in: PubMed
    Score: 0.124
  20. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Hum Pathol. 2014 Oct; 45(10):1995-2005.
    View in: PubMed
    Score: 0.121
  21. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol. 2014 Apr; 141(4):559-72.
    View in: PubMed
    Score: 0.119
  22. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014 Feb; 27(2):314-27.
    View in: PubMed
    Score: 0.113
  23. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012 Jul; 138(1):153-6.
    View in: PubMed
    Score: 0.105
  24. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. J Mol Diagn. 2011 Nov; 13(6):678-86.
    View in: PubMed
    Score: 0.099
  25. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011 Jan; 135(1):35-45.
    View in: PubMed
    Score: 0.095
  26. Microsatellite instability and high tumor mutational burden detected by next generation sequencing are concordant with loss of mismatch repair proteins by immunohistochemistry. Cancer Genet. 2024 Dec 15; 290-291:44-50.
    View in: PubMed
    Score: 0.062
  27. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol. 2024 Dec; 99(12):2416-2419.
    View in: PubMed
    Score: 0.062
  28. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in?situ hybridization. Cancer Cytopathol. 2024 Jan; 132(1):41-49.
    View in: PubMed
    Score: 0.057
  29. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.
    View in: PubMed
    Score: 0.056
  30. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.
    View in: PubMed
    Score: 0.055
  31. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
    View in: PubMed
    Score: 0.055
  32. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. Cancer. 2023 03 15; 129(6):878-889.
    View in: PubMed
    Score: 0.054
  33. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel). 2022 Dec 21; 12(1).
    View in: PubMed
    Score: 0.054
  34. Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers (Basel). 2022 Sep 20; 14(19).
    View in: PubMed
    Score: 0.053
  35. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica. 2022 09 01; 107(9):2232-2237.
    View in: PubMed
    Score: 0.053
  36. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
    View in: PubMed
    Score: 0.052
  37. Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. Ann Diagn Pathol. 2022 Aug; 59:151951.
    View in: PubMed
    Score: 0.052
  38. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol. 2022 Feb; 56:151860.
    View in: PubMed
    Score: 0.050
  39. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
    View in: PubMed
    Score: 0.050
  40. CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers (Basel). 2021 Oct 26; 13(21).
    View in: PubMed
    Score: 0.050
  41. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.
    View in: PubMed
    Score: 0.048
  42. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
    View in: PubMed
    Score: 0.047
  43. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Ann Diagn Pathol. 2021 Feb; 50:151649.
    View in: PubMed
    Score: 0.047
  44. Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Ann Diagn Pathol. 2020 Dec; 49:151636.
    View in: PubMed
    Score: 0.047
  45. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020 08 26; 10(8):86.
    View in: PubMed
    Score: 0.046
  46. Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. Mod Pathol. 2020 06; 33(6):1104-1121.
    View in: PubMed
    Score: 0.044
  47. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med. 2020 02; 9(3):849-858.
    View in: PubMed
    Score: 0.044
  48. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res. 2019 11; 86:106227.
    View in: PubMed
    Score: 0.043
  49. Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leuk Res. 2019 09; 84:106176.
    View in: PubMed
    Score: 0.043
  50. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.
    View in: PubMed
    Score: 0.042
  51. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
    View in: PubMed
    Score: 0.042
  52. Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. Mod Pathol. 2019 01; 32(1):16-26.
    View in: PubMed
    Score: 0.041
  53. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.
    View in: PubMed
    Score: 0.040
  54. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol. 2018 11; 31(11):1717-1732.
    View in: PubMed
    Score: 0.040
  55. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.
    View in: PubMed
    Score: 0.039
  56. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget. 2018 Feb 02; 9(9):8441-8449.
    View in: PubMed
    Score: 0.039
  57. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget. 2018 02 13; 9(12):10259-10271.
    View in: PubMed
    Score: 0.038
  58. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol. 2017 Dec; 99(6):536-543.
    View in: PubMed
    Score: 0.038
  59. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079.
    View in: PubMed
    Score: 0.038
  60. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One. 2017; 12(8):e0181968.
    View in: PubMed
    Score: 0.037
  61. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017 10; 30(10):1367-1377.
    View in: PubMed
    Score: 0.037
  62. Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol. 2017 Aug; 92(8):E175-E177.
    View in: PubMed
    Score: 0.037
  63. Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524.
    View in: PubMed
    Score: 0.037
  64. Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.
    View in: PubMed
    Score: 0.037
  65. Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet. 2017 04; 212-213:24-31.
    View in: PubMed
    Score: 0.036
  66. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857.
    View in: PubMed
    Score: 0.036
  67. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol. 2017 05; 30(5):734-744.
    View in: PubMed
    Score: 0.036
  68. Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017 04; 30(4):499-508.
    View in: PubMed
    Score: 0.036
  69. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn. 2017 03; 19(2):255-264.
    View in: PubMed
    Score: 0.036
  70. Coexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases. Mol Cytogenet. 2016; 9:84.
    View in: PubMed
    Score: 0.036
  71. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479.
    View in: PubMed
    Score: 0.035
  72. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn. 2016 09; 18(5):676-687.
    View in: PubMed
    Score: 0.035
  73. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Arch Pathol Lab Med. 2016 11; 140(11):1225-1227.
    View in: PubMed
    Score: 0.034
  74. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Arch Pathol Lab Med. 2016 Nov; 140(11):1228-1230.
    View in: PubMed
    Score: 0.034
  75. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genet. 2016 05; 209(5):205-14.
    View in: PubMed
    Score: 0.034
  76. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 2016 Mar 22; 7(12):14251-8.
    View in: PubMed
    Score: 0.034
  77. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leuk Lymphoma. 2016; 57(4):812-9.
    View in: PubMed
    Score: 0.034
  78. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol. 2016 06; 52:61-7.
    View in: PubMed
    Score: 0.034
  79. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol Cytogenet. 2015; 8:68.
    View in: PubMed
    Score: 0.033
  80. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015 Nov; 123(11):659-68.
    View in: PubMed
    Score: 0.033
  81. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
    View in: PubMed
    Score: 0.032
  82. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol. 2015 Apr; 39(4):454-61.
    View in: PubMed
    Score: 0.032
  83. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
    View in: PubMed
    Score: 0.032
  84. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw. 2015 Jan; 13(1):19-22.
    View in: PubMed
    Score: 0.031
  85. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.
    View in: PubMed
    Score: 0.031
  86. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.
    View in: PubMed
    Score: 0.031
  87. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer. 2014 Nov 11; 111(10):2014-23.
    View in: PubMed
    Score: 0.031
  88. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.031
  89. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504.
    View in: PubMed
    Score: 0.029
  90. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73.
    View in: PubMed
    Score: 0.029
  91. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61.
    View in: PubMed
    Score: 0.029
  92. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013 Sep; 15(5):607-22.
    View in: PubMed
    Score: 0.028
  93. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia. 2014 Jan; 28(1):185-9.
    View in: PubMed
    Score: 0.028
  94. Phenotypic evolution in a case of peripheral T-cell lymphoma suggests the presence of tumor heterogeneity. J Cutan Pathol. 2013 Jun; 40(6):573-9.
    View in: PubMed
    Score: 0.028
  95. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013 Mar; 15(2):220-6.
    View in: PubMed
    Score: 0.027
  96. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013 Jul; 54(7):1552.
    View in: PubMed
    Score: 0.027
  97. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45.
    View in: PubMed
    Score: 0.026
  98. Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med. 2012 May; 136(5):510-6.
    View in: PubMed
    Score: 0.026
  99. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S17-24.
    View in: PubMed
    Score: 0.024
  100. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006 Feb; 20(2):280-5.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.